您现在的位置: 首页   -  产品中心   -  免疫学   -   抗体
Biotinylated Ephrin-A3 Fc&Avi Tag Protein, Human

Biotinylated Ephrin-A3 Fc&Avi Tag Protein, Human

货号: UA010846
价格: 2780
规格: 25μg
介绍: -
其他: -
产品规格
  • 物种

    Human
  • 分子别名

    Ephrin-A3, EFL-2, EHK1-L, LERK-3, EFNA3
  • Accession

    P52797-1
  • 表达序列

    Gln23-Ser213, with C-terminal hIgG1 Fc and Avitag
  • 表达宿主

    HEK293
  • 分子量

    60-70kDa (Reducing)
  • 纯度

    >95% by SDS-PAGE
  • 内毒素含量

    <1EU/μg
  • 性状

    Lyophilized Powder
  • 缓冲体系

    PBS, pH7.4.
  • 溶解方法

    Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
  • 储存条件

    · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
    · 3 months, -20 to -80℃ under sterile conditions after reconstitution.
    · 1 week, 2 to 8℃ under sterile conditions after reconstitution.
    · Please avoid repeated freeze-thaw cycles.
  • 文献引用

    1. Keith K. Murai, Louis N. Nguyen, Fumitoshi Irie, Yu Yamaguchi & Elena B. Pasquale: Control of hippocampal dendritic spine morphology through ephrin-A3/EphA4 signaling, Nature Neuroscience volume 6, pages153–160 (2003).

  • 稀释度

背景介绍
  • Eph receptors compose the largest family of receptor tyrosine kinases (RTKs), which are capable of recognizing signals from the cell environment and influencing cell-cell interaction and cell migration. Ephrins are the ligands to Eph receptors and they stimulate bi-directional signaling of the Eph-ephrin axis. Ephrin-A3 (EFNA3) is one of the ephrin ligands which could bind to EphA2, EphA3, EphA5, EphA7, EphA8 and more poorly to EphA4. It is not only expressed in skeletal muscle, spleen, thymus, prostate, testis, ovary, small intestine and peripheral blood leukocytes, but is also present in neuroblastomas, neural cancers and leukemias. The dysregulated expression of EFNA3 has been observed in many types of human cancer. The expression level of EFNA3 was found to be upregulated 26-fold in squamous cell lung carcinoma, 3.8-fold in liver cancer, 1.6-fold in colon cancer and downregulated 2.6-fold in kidney carcinoma, respectively.

  • 电泳JSON

    • 1μg (R: reducing condition, N: non-reducing condition).